Oragenics Inc. (NYSE American: OGEN) provided a shareholder update on Wednesday, detailing progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI). The company announced that patient enrollment and dosing are active across multiple sites in Australia, with preparations underway for U.S. regulatory engagement. Oragenics plans to request a Type C meeting with the U.S. Food and Drug Administration in the second quarter of 2026, followed by an Investigational New Drug (IND) submission targeted by year-end 2026.
ONP-002 is a potential first-in-class treatment designed for acute administration following concussion, delivered via Oragenics' proprietary intranasal technology. The company believes this delivery method enables rapid brain targeting, which may address significant unmet needs in neurological care. The Phase IIa trial in Australia is evaluating safety and efficacy, with data expected to support the U.S. regulatory pathway.
Beyond its lead candidate, Oragenics disclosed a letter of intent to pursue licensing of a complementary central nervous system (CNS)-related medical device. This move signals an expansion beyond drug development into device-based therapies for neurological conditions. The company did not specify the device type but noted it aligns with its focus on CNS disorders.
Financially, Oragenics reported a cash balance of $6.1 million as of March 31, 2026. This funding is expected to support ongoing clinical activities and strategic initiatives, including the potential device licensing. The company's cash position reflects its ability to advance near-term milestones while exploring additional opportunities in the CNS space.
Oragenics’ intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The company is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.
The full press release is available at https://ibn.fm/tEk2C. For the latest news and updates relating to OGEN, visit the company’s newsroom at https://ibn.fm/OGEN.
